0
New
New
2022
Diabetic Nephropathy Market

Diabetic nephropathy Market by Drugs Class (Angiotensin-converting Enzyme Inhibitors, Angiotensin Receptor Blockers, Calcium Channel Blocker, Diuretics, Renin Inhibitor, Others), by Type (Type-1 Diabetes, Type-2 Diabetes), by Distribution Channel (Hospital Pharmacy, Online Providers, Drug Stores and Retail Pharmacy): Global Opportunity Analysis and Industry Forecast, 2021-2031

A16604
Pages: 266
Jun 2022 | 374 Views
Author(s) : Swapna Singh , Onkar Sumant
Tables: 150
Charts: 61
  • Formats*:

  • SIngle User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • It comes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Diabetic Nephropathy Market

Request Now !

Diabetic Nephropathy Market Research, 2031

The global diabetic nephropathy market was valued at $1.9 billion in 2021, and is projected to reach $3.3 billion by 2031, growing at a CAGR of 6% from 2022 to 2031.

Diabetic nephropathy is a long-term kidney disease that can affect people with diabetes. It occurs when high blood glucose levels damages kidney functions. It can occur in people with type-2 diabetes. Diabetic nephropathy is caused by damage to the tiniest blood vessels. When small blood vessels begin to develop damage, both kidneys begin to leak proteins into the urine. As damage to the blood vessels continues, the kidneys gradually lose their ability to remove waste products from the blood. It occurs when high blood glucose levels damage kidney function. Up to 40% of people with type-1 diabetes eventually develop significant kidney diseases, which sometimes requires dialysis or a kidney transplant. Only 4 to 6 % of all type-2 diabetes patients end up requiring dialysis, although about 20–30% of people with type-2 diabetes develop at least some kidney damage. About 40% of all people who need to start dialysis have kidney failure from type-1 or type-2 diabetes.

The diabetic nephropathy is diagnosed by different test such as urinary albumin test, albumin/creatinine ratio, and glomerular filtration rate (GFR), and other special tests includes imaging tests (CT scanning, MRI) and Kidney biopsy.

The COVID-19 outbreak is anticipated to have a negative impact on the diabetic nephropathy Market, as huge number of medical college and hospitals across the globe were restructured to increase the hospital capacity for patients diagnosed with COVID-19. The COVID-19 epidemic had a negative impact on the diabetic nephropathy market because priority is given to COVID-19 patient for treatment. Discovery and development of diabetic nephropathy medicine is slowing down during pandemic but did not stop

 

Diabetic Nephropathy Market, Diabetic nephropathy Market size, Diabetic nephropathy Market share, Diabetic nephropathy Market trends, Diabetic nephropathy Market growth, Diabetic nephropathy Market analysis, Diabetic nephropathy Market forecast, Diabetic nephropathy Market opportunity

Get more information on this report : Request Sample Pages

The major factors that drive the diabetic nephropathy market is surge in number of geriatric populations suffering from diabetic nephropathy, continuous increase in range of conditions that can be treated by diabetic nephropathy medicine and rise in demand of anti-diabetic medicine. This market also increased due to rise in incidence rates of various kidney diseases and rise in testing, which are expected to offer lucrative opportunities for market expansion.

Diabetic nephropathy can be controlled by taking medication, low protein diet, adopt healthy lifestyle, exercise and proper checkup that are preventing from kidney failure. Furthermore, diabetic nephropathy medicine work by controlling the blood glucose level, lowering cholesterol level and lowering to high blood pressure (hypertension). Due to wide application of diabetic nephropathy medicine and increasing the diagnostic tests of diabetic nephropathy are led to the growth of diabetic nephropathy market share. Moreover, increase in initiatives by governments & non-governmental organizations to promote awareness about diabetic nephropathy significantly contributes toward the growth of the industry.

However, the sales of diabetic nephropathy medicine have witnessed hindrances, owing to lack of skilled professionals for treatment of diabetic nephropathy in emerging and less developed countries, poor planning of diabetic nephropathy treatment in low-income countries are the key factors restraining the market. Strict regulatory rules regarding selling and lengthy approval time for drugs for diabetic nephropathy are also hamper the market growth. Due to these factors, the sales of premium diabetic nephropathy product are minimum. Conversely, the introduction of new medicine of diabetic nephropathy into developing nations is anticipated to offer remunerative opportunities for the expansion of the global market during the forecast period.

Furthermore, the healthcare business in developing nations is predicted to grow significantly as a result of various reasons, including increased investment in both the public and private sectors, rise in chronic diseases, surge in number of diabetes cases, and population expansion. Furthermore, an increase in healthcare spending is expected to promote the expansion of the healthcare business, which, in turn, is expected to fuel product demand.

The significant reduction in clinical trials due to strict government guidelines against COVID-19. Dialysis and transplant of kidney operation in diabetic nephropathy patient were postponed and home care setting care was preferred. Furthermore, the lockdown led to the disruption of manufacturing and transportation of healthcare essentials. According to FDA data that was published in 2019, approximately 40% pharmaceutical manufacturing unit established in India and China for the active pharmaceutical ingredient. Therefore, it has severely impacted to the supply chain of drugs.

The diabetic nephropathy market is segmented into Drugs Class, Type and Distribution Channel.

 On the basis of drug class, the market is classified into angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blocker, diuretics, renin inhibitor and others. By type, the market is segregated into type-1 diabetes, & type-2 diabetes. Depending on distribution channel, it is fragmented into hospital pharmacy, online providers, and drug & retail pharmacy.

Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA)

Segment Review

Depending on drug class, in diabetic nephropathy market size, the angiotensin-converting enzyme inhibitors segment was the highest revenue contributor in the global market in 2021, owing to rise in number of temporary as well as permanent chronic heart disease, heart attack, hypertension and diabetic nephropathy. The diuretics segment is expected to witness highest CAGR of 7.4% during the forecast period owing to rise in awareness and surge in cases of oedema, hypertension, kidney stones and diabetic nephropathy.

Diabetic nephropathy Market
By Drugs Class

Your browser does not support the canvas element.

The angiotensin-converting enzyme inhibitors segment held the largest share in the diabetic nephropathy market in 2021

Get more information on this report : Request Sample Pages

On the basis of type of diabetic nephropathy, the type-2 diabetes segment generated maximum revenue in 2021, owing to surge in diabetes cases and increase in awareness and diagnosis of diabetic nephropathy. The type-2 diabetes segment is also expected to witness highest CAGR during the diabetic nephropathy market forecast period.

Diabetic nephropathy Market
By Type

Your browser does not support the canvas element.

The type-2 diabetes segment held the largest share in the diabetic nephropathy market in 2021

Get more information on this report : Request Sample Pages

On the basis of distribution channel, in diabetic nephropathy market size, the drug stores & retail pharmacy segment was the highest revenue contributor to the market in 2021. The online providers segment is expected to witness highest CAGR during the forecast period, owing to increase in population suffering from diabetes and geriatric population.

Diabetic nephropathy Market
By Distribution Channel

Your browser does not support the canvas element.

The drug stores & retail pharmacy segment held the largest market share in 2021

Get more information on this report : Request Sample Pages

Depending on region, the North America generated maximum revenue in 2021, owing to increase in the number of patient admissions, and chronic kidney diseases. Asia-Pacific is expected to witness highest CAGR during the forecast period, owing to surge in number of diabetic nephropathy cases, chronic heart disease cases, and increase in prevalence of hypertension.

Diabetic nephropathy Market
By Region

2031
North America 
Europe
Asia-pacific
Lamea

North America held the largest market share in 2021

Get more information on this report : Request Sample Pages

The key players operating in the diabetic nephropathy industry are Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Bayer Ag, Eli Lilly and Company, Merck & Co, Inc., Novartis Ag, Pfizer Inc., Reata Pharmaceuticals, Inc., and Sanofi

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the diabetic nephropathy market analysis from 2021 to 2031 to identify the prevailing diabetic nephropathy market opportunity.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the diabetic nephropathy market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global diabetic nephropathy market trends, key players, market segments, application areas, and diabetic nephropathy market growth strategies.

Key Market Segments

  • By Drugs Class
    • Angiotensin-converting Enzyme Inhibitors
    • Angiotensin Receptor Blockers
    • Calcium Channel Blocker
    • Diuretics
    • Renin Inhibitor
    • Others

  • By Type
    • Type-1 Diabetes
    • Type-2 Diabetes

  • By Distribution Channel
    • Hospital Pharmacy
    • Online Providers
    • Drug Stores and Retail Pharmacy

  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • Germany
      • France
      • U.K.
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • Japan
      • China
      • Australia
      • India
      • South Korea
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • Saudi Arabia
      • South Africa
      • Rest of LAMEA

Key Market Players

  • AbbVie Inc.
  • Abbott Laboratories
  • Bayer AG
  • Eli Lilly and Company
  • Merck & Co
  • Astrazenica Plc
  • Novartis AG
  • Pfizer Inc.
  • Reata Pharmaceuticals
  • Sanofi
 

Loading Table Of Content...


 
 

This section provides opinions of top level CXOs in the diabetic nephropathy market. According to insights of CXOs, diabetic nephropathy is gaining high traction in the market, owing to increase in prevalence of diabetes and obesity, rise in R&D investments in drug discovery & development, and increase in awareness regarding diabetes & kidney-related disorders. Furthermore, key players in the market are focusing on adopting strategies to increase accessibility and utilization of diabetic nephropathy products in developing economies.

CXOs further added that diabetic nephropathy medicines provide relief from inflammation and help in lowering blood glucose level and preventing from chronic renal disease. Anti-diabetic nephropathy medicine is also lower to cholesterol level and maintaining blood pressure. Furthermore, experts of key companies believe surge in geriatric population, which is more prone to diabetic nephropathy diseases that require advanced treatment such as dialysis and transplant and rise in cases of diabetic nephropathy in adults may require temporary or permanent diabetic nephropathy treatment, thus increasing utilization of medicines. The market gains interest of healthcare companies, owing to its unmet demands in developing economies such as India and China where the population is growing rapidly along with diabetes load.

North America is expected to witness highest growth, in terms of revenue, owing to increase in cases of diabetes, robust healthcare infrastructure, presence of key players, and rise in healthcare expenditure. However, Asia-Pacific is anticipated to witness notable growth, owing to rise in geriatric population, unmet medical demands, initiatives by government & non-governmental organizations (NGOs) to promote awareness regarding diabetic nephropathy, and increase in public–private investments in the healthcare sector

Flash Sale
PURCHASE OPTIONS

Start reading instantly ,This Report and over 13000+ more Reports, Available with Avenue Library, T&C*

Call or Email us

U.S.-Canada
Toll-free :
+1-800-792-5285
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email : help@alliedmarketresearch.com
 
FREQUENTLY ASKED QUESTIONS?

A. The total market value of Diabetic Nephropathy is $3,338.5 million in 2031.

A. Top companies such as Abbott Laboratories, AstraZeneca Plc, Bayer Ag, Eli Lilly and Company, Merck & Co, Inc., Novartis Ag, Pfizer Inc.. held a high market position in 2021. These key players held a high market postion owing to the strong geographical foothold in U.S., Europe and LAMEA.

A. The diuretics segment is the most influencing segment owing to rise in awareness and surge in cases of oedema, hypertension, kidney stones and diabetic nephropathy.

A. The forecast period for Diabetic Nephropathy is 2022 to 2031.

A. The market value of Diabetic Nephropathy in 2021 is $1,863.17 million.

A. Yes, the Diabetic Nephropathy report provides PORTER Analysis.

A. The base year is 2021 in Diabetic Nephropathy.

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Request Free Sample
RELATED TAGS
 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Free Sample

OR

Purchase Full Report of
Diabetic Nephropathy Market

Start reading instantly.
This Report and over 13,000+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,456  $3,110
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,840  $3,456
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,769  $4,904
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,450  $5,483
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $10,995  $8,796
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library
    Membership

  • $ 999
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers